A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers

Single IV dose of GSK2862277

Single IV dose of GSK2862277

Single IV dose of GSK2862277

Single IV dose of GSK2862277

Matching placebo single dose IV infusion

Single IH dose of GSK2862277

Matching placebo single dose IH

Repeat IV dose of GSK2862277

Matching placebo repeat dose IV infusion

Repeat IH dose selected of GSK2862277 from Part 2

Matching placebo repeat dose IH

Safety and tolerability of single IV or IH dose of GSK2862277 assessed by number of subjects with adverse events (AE)s in Part 1 and Part 2

Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by number of subjects with AEs in Part 3

Safety and tolerability of single IV or IH dose of GSK2862277 assessed by laboratory tests in Part 1 and Part 2

Safety and tolerability of repeat IV or IH dose of GSK2862277 as assessed by laboratory tests in Part 3

Safety and tolerability of single IV or IH dose of GSK2862277 assessed by vital signs in Part 1 and Part 2

Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by vital signs in Part 3

Safety and tolerability of single IV or IH dose of GSK2862277 assessed by ECG in Part 1 and Part 2

Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by ECG in Part 3

Safety and tolerability of single IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 1 and Part 2

Safety and tolerability of repeat IV or IH dose of GSK2862277 assessed by spirometry monitoring in Part 3

Safety and tolerability of single IV dose of GSK2862277 as assessed by measurement of plasma cytokines in Part 1

Immunogenicity in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2

Immunogenicity in subjects receiving repeat IV or IH dose of GSK2862277 in Part 3

Pharmacokinetic (PK) parameters in subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2

PK parameters in subjects receiving repeat IV dose of GSK2862277 in Part 3 Cohort 3a

PK parameters in subjects receiving repeat IH dose of GSK2862277 in Part 3 Cohort 3b

PK parameters in subjects receiving single IV dose of GSK2862277 in Part 1

Pharmacodynamic and immune function biomarkers in serum of subjects receiving single IV or IH dose of GSK2862277 in Part 1 and Part 2

Pharmacodynamic and immune function biomarkers in serum of subjects receiving repeat IV or IH dose of GSK2862277in Part 3

Change from baseline in IL-8 expression in ex vivo WBA in subjects receiving single IV 0.05 mg/kg dose of GSK2862277 in Part 1 in Cohort1c

Composite of urine parameters in subjects receiving single IV 2 mg/kg dose of GSK2862277 in Part 2 in Cohort 2a